Seeking Alpha

Vertex Pharmaceuticals (VRTX) jumps 49% after the bell as the company says data from a Phase 2...

Vertex Pharmaceuticals (VRTX) jumps 49% after the bell as the company says data from a Phase 2 study of a combined corrector/potentiator treatment for cystic fibrosis patients with two copies of the F508del gene mutation showed "statistically significant, dose-dependent, improvements in lung function.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs